Immunexpress will partner with the DRIVe Solving Sepsis Initiative to develop and commercialize the Septicyte technology on Biocartis’ Idylla platform. DRIVe, which is an initiative of BARDA (Biomedical Advanced Research and Development Authority) in the U.S. Department of Health and Human Services will contribute almost $745,000 to this project. Sepsis causes millions of deaths globally each year and is the most common cause of death in people who have been hospitalized. Sepsis progresses rapidly and is difficult to diagnose accurately, leading to a need for better diagnostic tools. The sample-to-result assay being developed by Immunexpress with Biocartis will address this high unmet need for rapid, accurate diagnosis of sepsis. Immunexpress and Biocartis are Debiopharm Innovation Fund portfolio companies.